Get started
Author

Petra Schuberth

Observed names: P C Schuberth, P. C. Schuberth, P. Schuberth, Petra C Schuberth, Petra C. Schuberth, Schuberth, Petra C., Schuberth, Petra Christine
OpenAlex ID: A5008125030
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
2013 · Petra C Schuberth, Christian Hagedorn, et al. · Journal of Translational Medicine · 206
PDF
Induction of Exosome Release in Primary B Cells Stimulated via CD40 and the IL-4 Receptor
2008 · Sarah C Saunderson, Petra C Schuberth, et al. · The Journal of Immunology · 151
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
2020 · S. Hiltbrunner, C. Britschgi, et al. · Annals of Oncology · 98
PDF
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
2012 · Ulf Petrausch, Petra C Schuberth, et al. · BMC Cancer · 95
PDF
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
2022 · Bijal D. Shah, Armin Ghobadi, et al. · Journal of Hematology & Oncology · 82
PDF
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2018 · Pratiksha Gulati, Julia Rühl, et al. · Clinical Cancer Research · 71
PDF
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
2012 · P C Schuberth, G Jakka, et al. · Gene Therapy · 61
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
2022 · Alan S. Wayne, Van Huynh, et al. · Haematologica · 47
PDF
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
2023 · Bijal D Shah, Ryan D Cassaday, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: experience of the first patient treated
2015 · Magdalena Pircher, Petra Schuberth, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.
2022 · Bijal D. Shah, Armin Ghobadi, et al. · Journal of Clinical Oncology · 10
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
2013 · Gopinadh Jakka, Petra C Schuberth, et al. · PubMed · 10
Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2022 · Bijal D. Shah, Armin Ghobadi, et al. · Blood · 4
P356: Subgroup Analyses of Kte-x19, an Anti-cd19 Chimeric Antigen Receptor (car) T-cell Therapy, in Adult Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-all) in Zuma-3
2022 · B. D. Shah, R. D. Cassaday, et al. · HemaSphere · 4
P-002 Ide-Cel Real-World (RW) and Clinical Trial Long-Term Safety Experience: A Special Focus on Movement and Neurocognitive Treatment Adverse Events (MNT AEs) and Second Primary Malignancies (SPMs)
2024 · Rafat Abonour, Amani Kitali, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma
2024 · Surbhi Sidana, Christof Scheid, et al. · Blood · 1
Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies
2023 · Barbara Eichhorst, Kieron Dunleavy, et al. · Transplantation and Cellular Therapy · 1
Subgroup Analyses of Kte-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients (Pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in Zuma-3
2023 · Bijal D. Shah, Ryan D. Cassaday, et al. · Transplantation and Cellular Therapy · 1
O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3
2023 · Bijal D. Shah, Armin Ghobadi, et al. · Annals of Oncology
supplementary figure legends from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Figure S3 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Figure S1 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Figure S6 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Figure S2 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Figure S5 from Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice
2023 · Pratiksha Gulati, Julia Rühl, et al.
Works count: 45
Citation count: 891
H-index: 10
I10-index: 12
Year
Topic
Type